Lataz

Latanoprost, the active ingredient in Lataz, is a prostaglandin analog presented as a ophthalmic solution for ocular use. It treats open-angle glaucoma and ocular hypertension in adults by lowering intra‑ocular pressure. GNH USA supplies Lataz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lataz is a prostaglandin analog used to manage conditions that involve elevated intra‑ocular pressure. - Open‑angle glaucoma: lowers intra‑ocular pressure to protect the optic nerve and preserve visual field. - Ocular hypertension: reduces pressure to prevent progression to glaucoma. - Glaucoma suspect: helps maintain target pressure while monitoring for disease conversion.

Latanoprost may cause ocular and systemic reactions.

Common Side Effects: - Eye redness: mild hyperemia of the conjunctiva. - Increased eyelash length: longer, thicker lashes. - Darkening of iris: gradual pigmentation change. - Eye irritation: foreign‑body sensation or mild discomfort.

Serious or Rare Side Effects: - Severe allergic reaction: swelling, itching, or rash. - Uveitis or intra‑ocular inflammation. - Sudden increase in intra‑ocular pressure (paradoxical response).

Before using Lataz, consider the following precautions. - Monitor intra‑ocular pressure regularly: ensure therapeutic effect and detect paradoxical rise. - Avoid use in active ocular infection: may exacerbate inflammation. - Caution in patients with a history of uveitis: risk of recurrence. - Not recommended for children unless specifically prescribed: safety not established. - Do not wear contact lenses during treatment: may cause deposits. - Store at room temperature: keep in original container, protect from moisture and light.

Lataz can interact with other ophthalmic agents.

Major Interactions (Avoid): - Concurrent use with other prostaglandin analog eye drops: additive ocular side effects. - Use with ocular cycloplegics: may reduce therapeutic efficacy.

Moderate Interactions (Monitor Closely): - Combination with topical beta‑blockers: additive intra‑ocular pressure reduction. - Use with ocular steroids: increased risk of cataract or pressure spikes. - Contact lens wear during therapy: may cause lens deposits and reduced comfort.